Simvastatin Reduces Vaso-occlusive Pain in Sickle Cell Anaemia: a Pilot Efficacy Trial

Overview

Journal Br J Haematol

Specialty Hematology

Date 2017 Apr 4

PMID 28369718

Citations 30

Authors

Carolyn Hoppe

Eufemia Jacob

Lori Styles

Frans Kuypers

Sandra Larkin

Elliott Vichinsky

Affiliations

Soon will be listed here.

Abstract

Sickle cell anaemia (SCA) is a progressive vascular disease characterized by episodic vaso-occlusive pain. Despite the broad impact of inflammation on acute and chronic clinical manifestations of SCA, no directed anti-inflammatory therapies currently exist. Statins are cholesterol-lowering agents shown to confer protection from vascular injury by suppressing inflammation. We previously documented a reduction in soluble biomarkers of inflammation in patients with sickle cell disease treated with simvastatin. To determine the potential clinical efficacy of simvastatin, we treated 19 SCA patients with single daily dose simvastatin for 3 months and assessed changes from baseline in the frequency and intensity of diary-reported pain and levels of circulating nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), ICAM-3, E-selectin, and vascular endothelial growth factor (VEGF). Treatment with simvastatin resulted in a significant reduction in the frequency of pain (P = 0·0003), oral analgesic use (P = 0·003) and circulating hs-CRP (P = 0·003), soluble (s)E-selectin (P = 0·01), sICAM-1 (P = 0·02), sICAM-3 (P = 0·02) and sVEGF (P = 0·01). Simvastatin had no effect on pain intensity or levels of NOx, sP-selectin and sVCAM-1. The observed reductions in pain rate and markers of inflammation were greatest in subjects receiving hydroxycarbamide (HC), suggesting a synergistic effect of simvastatin. These results provide preliminary clinical data to support a larger trial of simvastatin in SCA.

Citing Articles

Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease.

Xi C, Palani C, Takezaki M, Shi H, Horuzsko A, Pace B Antioxidants (Basel). 2024; 13(3).

PMID: 38539870 PMC: 10968127. DOI: 10.3390/antiox13030337.

Evaluating Associations between Average Pain Intensity and Genetic Variation in People with Sickle Cell Disease: An Exploratory Study.

Knisely M, Yang Q, Stauffer N, Kenney M, Ashley-Koch A, Myers J Pain Manag Nurs. 2022; 24(1):12-18.

PMID: 36096903 PMC: 9925395. DOI: 10.1016/j.pmn.2022.08.002.

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.

Treadwell M, Du L, Bhasin N, Marsh A, Wun T, Bender M Front Genet. 2022; 13:921432.

PMID: 36092883 PMC: 9461276. DOI: 10.3389/fgene.2022.921432.

Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.

Hebbel R, Vercellotti G Am J Hematol. 2021; 96(11):1505-1517.

PMID: 34331722 PMC: 9292023. DOI: 10.1002/ajh.26308.

Severe Persistent Pain and Inflammatory Biomarkers in Sickle Cell Disease: An Exploratory Study.

Knisely M, Tanabe P, Walker J, Yang Q, Shah N Biol Res Nurs. 2021; 24(1):24-30.

PMID: 34189962 PMC: 9248289. DOI: 10.1177/10998004211027220.

References

ODriscoll G, Green D, Taylor R . Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95(5):1126-31. DOI: 10.1161/01.cir.95.5.1126. View

Kinlay S, Schwartz G, Olsson A, Rifai N, Szarek M, Waters D . Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2007; 28(1):142-7. DOI: 10.1161/ATVBAHA.107.151787. View

Jacob E, Stinson J, Duran J, Gupta A, Gerla M, Lewis M . Usability testing of a Smartphone for accessing a web-based e-diary for self-monitoring of pain and symptoms in sickle cell disease. J Pediatr Hematol Oncol. 2012; 34(5):326-35. PMC: 3382023. DOI: 10.1097/MPH.0b013e318257a13c. View

Palmer R, Ashton D, Moncada S . Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988; 333(6174):664-6. DOI: 10.1038/333664a0. View

Braman R, Hendrix S . Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem. 1989; 61(24):2715-8. DOI: 10.1021/ac00199a007. View

Makis A, Hatzimichael E, Stebbing J, Bourantas K . C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Arch Intern Med. 2006; 166(3):366-8. DOI: 10.1001/archinte.166.3.366. View

Smith W, Ballas S, Mccarthy W, Bauserman R, Swerdlow P, Steinberg M . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med. 2011; 12(5):697-705. PMC: 6818651. DOI: 10.1111/j.1526-4637.2011.01096.x. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C . Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014; 63(23):2491-2502. DOI: 10.1016/j.jacc.2014.01.054. View

10.

Shah S, Newby L . C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 2003; 11(4):169-79. DOI: 10.1097/01.CRD.0000077906.74217.6E. View

11.

Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L . A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011; 153(5):655-63. PMC: 3601917. DOI: 10.1111/j.1365-2141.2010.08480.x. View

12.

Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao J . Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002; 106(1):57-62. DOI: 10.1161/01.cir.0000020682.73694.ab. View

13.

Akinsheye I, Klings E . Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol. 2010; 224(3):620-5. DOI: 10.1002/jcp.22195. View

14.

Brown M, Allen J, Van Stavern G, Newman N, Wallace D . Clinical, genetic, and biochemical characterization of a Leber hereditary optic neuropathy family containing both the 11778 and 14484 primary mutations. Am J Med Genet. 2001; 104(4):331-8. View

15.

Blann A, Mohan J, Bareford D, Lip G . Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. J Thromb Thrombolysis. 2007; 25(2):185-9. DOI: 10.1007/s11239-007-0177-7. View

16.

Saleh A, Hillen H, Duits A . Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999; 102(1):31-7. DOI: 10.1159/000040964. View

17.

Owusu-Ansah A, Ihunnah C, Walker A, Ofori-Acquah S . Inflammatory targets of therapy in sickle cell disease. Transl Res. 2015; 167(1):281-97. PMC: 4684475. DOI: 10.1016/j.trsl.2015.07.001. View

18.

Duits A, Pieters R, Saleh A, van Rosmalen E, Katerberg H, Berend K . Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996; 81(1):96-8. DOI: 10.1006/clin.1996.0163. View

19.

Rees D, Cervi P, Grimwade D, ODriscoll A, Hamilton M, Parker N . The metabolites of nitric oxide in sickle-cell disease. Br J Haematol. 1995; 91(4):834-7. DOI: 10.1111/j.1365-2141.1995.tb05397.x. View

20.

Chi J, Chang H, Haraldsen G, Jahnsen F, Troyanskaya O, Chang D . Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A. 2003; 100(19):10623-8. PMC: 196854. DOI: 10.1073/pnas.1434429100. View